Search
Search
Brain tumors and brain metastasis of tumors are very difficult clinical situations. Brain tumors, represented by glioma, are one of the most difficult cancers to overcome at present. Even some brain tumors still have no effective treatment and the existing treatment pathways are largely unable to prevent a recurrence. Antibody-engineered drugs, which are the fastest growing in the field of biomedicine, have brought new light to the treatment of brain tumors.
Antibody-mediated immunotherapy is an important tool for immunotherapy of brain tumors, in addition to ICI, cancer vaccines, pericyte therapy, and lysing virus therapy. Alfa Cytology aims to provide our clients with antibody development services for brain tumors through our proven technology platform. These include PD-1/PD-L1 antibodies for immune checkpoint inhibitors, antibodies that inhibit the CD161-CLEC2D pathway, and 124I-8H9 monoclonal antibodies targeting B7-H3.
We provide monoclonal antibody drug development services for brain tumors. By encapsulating monoclonal antibodies in nanocapsules containing choline and acetylcholine analogs, we enable the nanocapsules to cross the blood-brain barrier and deliver monoclonal antibodies to the tumor site. It can effectively improve the therapeutic effects of monoclonal antibodies for various brain tumors.
We provide our clients with brain tumor peptide development services that are highly pure and safe. In addition, we have made it possible to make more peptides into anti-brain tumor drugs by introducing a ring structure to restrain the activity of the peptide and increase the stability of the peptide to show better pharmacological activity and stability.
We prepare efficient and highly specific anti-CD133 polyclonal antibodies, CD11c polyclonal antibodies, etc. for our customers. We offer polyclonal antibodies that are less expensive to prepare than monoclonal antibodies of the same species origin and have shorter preparation cycles.
We can prepare recombinant antibodies (chimeric antibodies, humanized antibodies, fully humanized antibodies, small molecule antibodies, and bispecific antibodies) for our customers for use in the field of brain tumor research, with antibody production time reduced to 1-2 months.
We provide customers with humanization services for antibodies used in brain tumor research, which allows antibodies to be used in brain tumor research with reduced human allogeneic rejection. In addition to this, we are actively trying to provide fully humanized brain tumor antibodies by using animal gene knockout and insertion and phage display technologies.
To expand the audience for antibody drugs, Alfa Cytology is actively conducting antibody drug miniaturization studies. We are trying to obtain Fab fragments, single-chain antibodies, bispecific antibodies, trivalent antibodies, and miniature antibodies by enzymatic digestion or genetic engineering.
Please contact our staff to learn how we develop highly effective and stable antibodies for brain tumor research and treatment.
Brain Tumors
Alfa Cytology has been committed to providing comprehensive services and products to our brain tumor research customers worldwide through our global network of operations.
Subscribe to Our Newsletter
Copyright © 2024 Alfa Cytology. All rights reserved.